Dr. Wang is United BioPharma's founder and chairwoman. She also serves as our Chief Scientific Officer. She is inventor of UBP's technology platform and her track record of development of innovative solutions for health applications are innumerous. Dr. Wang directed development of the first peptide based diagnostic kit: the first fully synthetic designer peptide vaccine, and one of the only endobody vaccines in the world.
Dr. Wang has over 100 issued patents (not including the patents in application) and has more than 120 peer reviewed scientific papers. She is founder of United Biomedical Inc. and has served as Chairperson of the Board since 1985.
Prior to switching into the world of pharmaceutical industry, Dr. Wang was Principal Investigator and Head of Laboratory of Molecular Immunology at the Memorial Sloan-Kattering Division, Cornell University Medical School. Dr. Wang has earned her PhD in Immunology and Biochemistry from the Rockerfeller University and received her B.S. degree in Chemistry from National Taiwan University.
Dr. Lynn, our Chief Executive Officer joined United BioPharma (UBP) in 2013. She has been with UBI Group since 1999 and is currently one of the Executive Committee and a member of its Board Directors. Dr. Lynn led development of humanized antibody, high-producing CHO Cell Line and process development for the antibody pipelines and played key part in leading UBP’s pipeline UB-421 into early stage clinical trial.
During Dr. Lynn’s tenure at UBI Asia, the company was awarded 11 government grants leading three pipelines into clinical trial stage. Dr. Lin earned her Ph.D. in Life Sciences from the Institute of Zoology at National Taiwan University and received BSc degree in Plant Pathology from National Taiwan Univesrity.
Dr. Liao brings a track record of over 30 years of experience in biopharmaceutical industry to UBP, Dr. Liao has been with the Company since 2014. Prior to United BioPharma, she was leader for Regulatory Affairs team and function at United Biomedical between 2008 to 2013.
Her enriched experience in Research and Development in the United States brings great value to our Organization. Dr. Liao international experience include VP R&D and Quality Control, VP Regulatory Affairs and Quality at Hemispherx Biopharma; VP R&D at Interferon Sciences, and Head Cellular Immunology Group at the same company. Dr. Liao has 45 full length articles published in peer reviewed journals and presented more than 70 abstracts in scientific conferences. Dr. Liao earned her PhD, Physical Biochemistry and MPh Physical Biochemistry from Yale University. Her B.S. Chemistry was obtained from National Tsing Hua University in Taiwan.
Dr. Liu is Vice President Research and Development at United BioPharma (UBP), having joined at UBP since 2013, Dr. Liu's key responsibilities include leading projects in the major areas of genetic engineering, molecular biology, protein biochemistry, formulation study and analytical method development.
He joined the UBI Group from 2005 as a research scientist and developed analytical test methods for the release and characterization of protein drug products. Dr. Liu and his team led the CMC preparation of protein and antibody products for IND submissions. Dr. Liu's track record include succesful transfer of five biological compounds from discovery translation to clinical stage. Dr. Liu received his Ph.D. degree in Department of Life Sciences, National Tsing Hua University,
Victor Sun joined UBP in 2014 as vice president of public affairs and spokesperson. Prior to that, he was the manager and assistant to the chair at Hua Yu Lien Development Co., Ltd., and deputy executive director for the Taipei Chamber of Commerce. Victor also served as the chief secretary for not only the Overseas Community Affairs Council, Taiwan (R.O.C. ) but also the National Palace Museum. Therefore, he has extensive experience of in dealing with government agencies , public policy and management, and public negotiation . Moreover, Victor is familiar with strategic planning and commercialization. He received his BS degree from the Department of Law at National Taiwan University.
Dr. Kuo Vice President Clinical Pharmacology, brings 30 years of track record in drug development that spans from monoclonal antibody, synthetic peptide vaccine, protein and small molecule compounds. Dr. Kuo's strong research and background experience include quantitative protein and cellular analysis, immuno pharmacology, pharmacokinetics and safety/toxicology studies.
Dr. Kuo's milestones in innovative drug research and development include 10+ monoclonal antibodies used in respiratory, immunology, infectious diseases and oncology therapeutic areas. Dr. Kuo was Senior Scientist in the United States for Marion Merrell Dow (now Sanofi), Parke Davis (now Pfizer), IDEC Pharmaceutical (now Biogen Idec). and as Senior Director in Taiwan for AbGenomics and Fountain Biopharma.
Dr. Kuo joined United Biomedical, Asia (UBIA) in 2009-2010 and subsequently joined UBP in 2014. Dr. Kuo graduated from Pharmacy School of Taipei Medical University and received his Ph. D. degree in Biopharmaceutics from the College of Pharmacy, University of Cincinnati, Ohio. He remained building his strong academic experience doing postdoctoral research in cardiovascular pharmacology at Duke University and Jefferson Medical Center. Dr. Kuo published 40 peer-reviewed scientific papers.